ItalyTuberculosis profile
Population  2016 59 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.33 (0.33–0.34) 0.56 (0.56–0.57)
Mortality (HIV+TB only) 0.063 (0.032–0.11) 0.11 (0.05–0.18)
Incidence  (includes HIV+TB) 3.7 (3.1–4.2) 6.1 (5.3–7.1)
Incidence (HIV+TB only) 0.41 (0.24–0.63) 0.69 (0.4–1.1)
Incidence (MDR/RR-TB)** 0.14 (0.095–0.19) 0.24 (0.16–0.32)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.14 (0.12–0.16) 1.2 (0.99–1.3) 1.3 (1.1–1.5)
Males 0.16 (0.13–0.18) 2.2 (1.9–2.5) 2.3 (2–2.7)
Total 0.3 (0.25–0.34) 3.4 (2.8–3.9) 3.7 (3.1–4.2)
TB case notifications, 2016  
Total cases notified 4 032
Total new and relapse 3 778
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status  
          - % pulmonary 69%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 100% (90–120)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.11 (0.09–0.13)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  110
(73–140)
Estimated % of TB cases with MDR/RR-TB 2.8% (1.8–4.3) 13% (7.7–21)  
% notified tested for rifampicin resistance 26% 47% 2 666
MDR/RR-TB cases tested for resistance to second-line drugs   55
Laboratory-confirmed cases MDR/RR-TB: 85, XDR-TB: 7
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New cases registered in 2015    
Previously treated cases registered in 2015    
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data